The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 6, 1996, Pages 1023-1029

  Bron, N J ^a   Dorr, M B ^a,b   Mant, T G ^c   Webb, C L ^a,b   Vassos, A B ^a  

^a Parke Davis Pharmaceutical Research   (United Kingdom)

^b Guy's Drug Research Unit ^*

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG TOLERANCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RASH; TIME; VERTIGO;

ADULT; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; FLUOROQUINOLONES; HUMANS; MALE; QUINOLONES;

EID: 0030466050     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.6.1023     Document Type: Article

References (10)

1. Aldridge, K. E. (1992). In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents. Antimicrobial Agents and Chemotherapy 36, 851-3.
2. Barrett, M. S. & Jones, R. N. (1992). Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae. European Journal of Clinical Microbiology and Infectious Diseases 11, 462-5.
3. Barren, M. S., Jones, R. N., Erwin, M. E., Johnson, D. M. & Briggs, B. M. (1991). Antimicrobial activity evaluations of two new quinolones. PD 127391 (CI-960 and AM-1091) and PD 131628. Diagnostic Microbiology and Infectious Disease 14, 389-401.
4. Barry, A. L. & Fuchs, P. C. (1991). Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 10, 168-71.
5. Fuchs, P. C., Barry, A. L., Pfaller, M. A., Allen, S. D. & Gerlach, E. H. (1991). Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 35, 764-6.
6. Gibaldi, M. & Perrier, D. (1982). Pharmacokineties, 2nd edn, pp. 50-1. Marcel Dekker, New York.
7. Goldstein, E. J. & Citron, D. M. (1992). Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990 and WIN 57273 against anaerobic bacteria. Antimicrobial Agents and Chemotherapy 36, 1158-62.
8. Gooding, B. B., Erwin, M. E., Barrett, M. S., Johnson, D. M. & Jones, R. N. (1992). Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates. Antimicrobial Agents and Chemotherapy 36, 2049-50.
9. Qadri, S. M. & Ueno, Y. (1993). Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs. Chemotherapy 39, 128-31.
10. Zeiler, H.-J., Beermann, D., Wingender, W., Förster, D. & Schacht, P. (1988). Bactericidal activity of ciprofloxacin, norfloxacin, and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection 16, Suppl. 1, 19-23.